HCRN Directory

Urothelial Carcinoma

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status

Cancer Types

Bladder

Locations

Columbia University Irving Medical Center, Fox Chase Cancer Center, Fred & Pamela Buffett Cancer Center, Indiana, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Iowa, Maryland, Missouri, Nebraska, New York, Pennsylvania, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, University of Iowa Holden Comprehensive Cancer Center

HCRN-GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status

Closed

Cancer Types

Bladder

Locations

HCRN-GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status

Closed

Cancer Types

Urothelial Carcinoma

Locations

HCRN-GU15-215

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Status

Closed

Cancer Types

Bladder

Locations

HCRN-GU15-217

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217

Status

Closed

Cancer Types

Bladder

Locations

HCRN-GU15-262

Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Status

Closed

Cancer Types

Bladder

Locations

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Status

Open to Accrual

Cancer Types

Bladder

Locations

Huntsman Cancer Institute at the University of Utah, Icahn School of Medicine at Mount Sinai, Maryland, New Jersey, New York, Rutgers Cancer Institute of New Jersey, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tennessee, Utah, Vanderbilt-Ingram Cancer Center

HCRN-GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Status

Closed

Cancer Types

Bladder

Locations

HCRN-GU17-294

Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade

Status

Closed

Cancer Types

Bladder

Locations